Asep Medical Holdings Inc. (OTCQB: SEPSF) announced the allowance of its European patent for SepsetER, a diagnostic technology addressing sepsis. This advancement supports commercialization across several European markets including Belgium, France, and Germany upon regulatory approval. SepsetER can diagnose severe sepsis within 1-2 hours, outpacing current tests that take 24-48 hours, potentially improving patient outcomes significantly. Asep’s Chairman highlighted this milestone as beneficial to shareholder value.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) announced on June 7, 2022, the revocation of a Failure-to-File Cease Trade Order (FFCTO) by the British Columbia Securities Commission effective June 1, 2022. The company filed all necessary documents by May 30, 2022, and is now authorized to trade on the Canadian Securities Exchange. CEO Rudy Mazzocchi expressed gratitude for the efforts made to resolve the filing issue, emphasizing a focus on business development and commercialization to enhance shareholder value.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) has announced delays in filing its annual financial statements due to resource limitations caused by COVID-19 and the integration of its recent acquisitions. Consequently, the British Columbia Securities Commission issued a Cease Trade Order (CTO), halting trading of the company's stock. Asep expects to file the required documents within 7-10 days and will follow alternative information guidelines during this period. The firm specializes in developing diagnostics and treatments related to severe sepsis and multidrug-resistant infections.
Asep Medical Holdings Inc. (OTCQB: SEPSF) has successfully listed on the OTCQB Venture Market, enhancing its visibility to U.S. investors. Trading commenced on April 21, 2022. The company also secured an account with the Depository Trust Company, facilitating liquidity and transaction processing. Chairman Rudy Mazzocchi stated the listing aims to diversify the investor base and improve valuation for their therapeutic and diagnostic technologies, especially their innovative solutions targeting severe sepsis. The OTCQB listing represents a crucial milestone in the company's growth strategy.